financetom
Business
financetom
/
Business
/
Steven Madden's Q2 Adjusted Earnings, Net Sales Increase
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Steven Madden's Q2 Adjusted Earnings, Net Sales Increase
Jul 31, 2024 6:58 AM

09:42 AM EDT, 07/31/2024 (MT Newswires) -- Steven Madden (SHOO) reported Q2 adjusted earnings Wednesday of $0.57 per diluted share, up from $0.47 a year earlier.

Analysts polled by Capital IQ expected $0.51.

Net sales for the quarter ended June 30 were $521.7 million compared with $442.8 million a year earlier.

Analysts polled by Capital IQ expected $518 million.

The company reiterated its full-year forecast of $2.55 to $2.65 in adjusted earnings per share and 11% to 13% in revenue growth. Analysts polled by Capital IQ expect $2.63 in adjusted earnings per share on revenue of $2.23 billion.

Price: 43.77, Change: -0.69, Percent Change: -1.55

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pason Systems Renews Normal Course Issuer Bid
Pason Systems Renews Normal Course Issuer Bid
Dec 18, 2024
07:53 AM EST, 12/18/2024 (MT Newswires) -- Pason Systems ( PSYTF ) overnight Tuesday said the Toronto Stock Exchange approved the extension of it's normal course issuer bid. The new NCIB will start on Friday and will end on Dec. 19, 2025, or earlier if the bid is completed or terminated by Pason ( PSYTF ). The bid renews the...
Swiss report on Credit Suisse collapse to be published Friday
Swiss report on Credit Suisse collapse to be published Friday
Dec 18, 2024
ZURICH, Dec 18 (Reuters) - A Swiss parliamentary report into how authorities managed the 2023 collapse of Credit Suisse will be published on Friday, the Swiss parliament said on Wednesday. The report by the parliamentary committee looking into the Credit Suisse meltdown has been eagerly awaited for months and the government says its findings will feed into new rules due...
Merck signs deal worth up to $2 bln with China's Hansoh for oral obesity drug
Merck signs deal worth up to $2 bln with China's Hansoh for oral obesity drug
Dec 18, 2024
Dec 18 (Reuters) - Merck ( MRK ) on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's experimental oral obesity drug that works similar to the popular weight-loss treatments Wegovy and Zepbound. Merck ( MRK ) said it will pay $112 million upfront for an exclusive license to the...
Agios Pharmaceuticals Says Mitapivat Granted EU Orphan Drug Status for Sickle Cell Disease
Agios Pharmaceuticals Says Mitapivat Granted EU Orphan Drug Status for Sickle Cell Disease
Dec 18, 2024
07:53 AM EST, 12/18/2024 (MT Newswires) -- Agios Pharmaceuticals ( AGIO ) said Wednesday that the European Commission has granted orphan medicinal product designation to mitapivat, its oral small-molecule PK activator, for treating sickle cell disease. The company said it plans to share results of its phase 3 study assessing the efficacy and safety of mitapivat in late 2025. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved